Short answer
What is Sermorelin? Sermorelin is the synthetic N-terminal fragment of growth hormone-releasing hormone consisting of residues 1 through 29, usually supplied as GHRH(1-29)-NH2 (GRF 1-29 amide). It is a GHRH receptor agonist studied in growth hormone and endocrine research. It is sold as a lyophilized research powder and is not for human use.
What is Sermorelin?
Sermorelin is a 29-amino-acid peptide corresponding to the biologically active N-terminal portion of growth hormone-releasing hormone (GHRH), the hypothalamic hormone that controls growth hormone release. The full GHRH peptide is 44 amino acids long, but the first 29 residues carry the receptor-activating pharmacophore, and the C-terminal portion is largely dispensable for activity. Sermorelin is this active fragment, typically produced as the amidated form GHRH(1-29)-NH2, also known as GRF 1-29 amide.
The peptide has a molecular weight of approximately 3358 g/mol and a CAS registry number of 86168-78-7. It belongs to the family of growth hormone-releasing peptides that includes the modified analog CJC-1295 and the full-length analog tesamorelin. Because it is the direct descendant of the native hormone's active site, Sermorelin is often used as a reference compound in GHRH receptor research.
Mechanism of action
Sermorelin binds to the growth hormone-releasing hormone receptor (GHRHR), a G-protein-coupled receptor on pituitary somatotroph cells. Receptor activation initiates the G alpha-s/adenylyl cyclase/cAMP/protein kinase A signaling cascade, which stimulates both the synthesis of growth hormone and its release into circulation [1].
A critical feature of Sermorelin's mechanism is that it requires an intact pituitary. It does not deliver growth hormone itself; it stimulates the pituitary to produce it. This means the response depends on functional somatotroph cells and an intact GHRH receptor-signaling pathway. In research contexts this is often the point of interest: Sermorelin is a tool for interrogating pituitary responsiveness to GHRH-receptor stimulation, upstream of growth hormone itself.
Research history
The study of GHRH(1-29) in endocrine research dates back to the 1980s. The pivotal early study was published by Ross and colleagues in the Lancet in 1987, which administered GHRH(1-29)-NH2 to 18 prepubertal growth-hormone-deficient children and demonstrated that the fragment could stimulate growth [1]. This established the concept that the 29-residue fragment retained the biological activity of the full hormone and opened a line of research that continued for two decades.
By the mid-1990s, multicenter trials had consolidated the picture. The Geref International Study Group reported on once-daily subcutaneous GHRH(1-29) in growth-hormone-deficient children and found that it accelerated growth during the first year of administration, with approximately three-quarters of children classified as responders and an increase in height velocity from roughly 4.1 cm per year to about 8.0 cm per year [2].
Comparative studies examined how the fragment performed against growth hormone itself. A randomized study in 60 children with growth hormone deficiency of hypothalamic origin compared GHRH(1-29)-NH2 at two doses against recombinant growth hormone, finding that while the growth hormone arm grew somewhat faster, the GHRH arms still achieved clinically meaningful growth acceleration, with no significant difference between the two GHRH doses [3].
A further strand of research extended the work to children with idiopathic short stature, who have normal growth hormone responses to stimulation testing but slow growth. A 1994 study reported that GHRH(1-29)-NH2 produced a sustained increase in growth velocity in this group, broadening the clinical relevance of the compound beyond classic growth hormone deficiency [4].
For the modern researcher, this literature matters less for its historical clinical conclusions and more for what it documents about GHRH receptor biology: the dose-response behavior of GHRH(1-29), the relationship between pituitary responsiveness and downstream growth, and the fact that receptor stimulation can sustain hormone output over months.
Sermorelin compared with related GHRH pathway peptides
Sermorelin sits within a family of growth hormone pathway research peptides, and the differences between them are instructive:
The practical question for a research protocol is whether a short-acting reference peptide (Sermorelin), a DPP-IV-resistant analog (CJC-1295 no DAC), or a long-acting albumin-conjugated analog (CJC-1295 with DAC) best matches the intended experimental time course.
The growth hormone axis and its regulation
Growth hormone output is regulated by a three-way hypothalamic-pituitary balance: GHRH stimulates release, somatostatin inhibits it, and ghrelin-receptor signaling modulates it. Growth hormone then drives IGF-I production in the liver and periphery, and IGF-I feeds back to restrain further growth hormone release. This is the somatotropic axis, and it is central to research on body composition, metabolism, and aging.
Sermorelin acts at the first step of this circuit, engaging the GHRH receptor at the pituitary. Because the axis is a closed feedback loop, stimulating it at the receptor level produces a cascade: growth hormone rises, IGF-I rises, and feedback dampens the response over time. Researchers study this cascade when they want to understand how the hypothalamus-pituitary-liver circuit responds to a defined GHRH-receptor stimulus, or when they need a growth hormone secretagogue with a precisely characterized receptor pharmacology.
The pituitary-dependence of the mechanism is a useful experimental property. Because Sermorelin cannot act without functional somatotroph signaling, it is a probe for pituitary function itself. Studies of cells or animals with impaired pituitary signaling can use Sermorelin to determine whether the deficit lies at the pituitary or higher in the hypothalamus.
Dose-response behavior and pituitary responsiveness
A central theme in the GHRH(1-29) literature is the relationship between the amount of peptide administered and the growth hormone response it produces. The randomized comparative study discussed above found no significant difference between the two GHRH doses tested, suggesting a ceiling effect once receptor occupancy saturates [3]. This saturability is a property of the receptor pharmacology: at high concentrations essentially all available GHRH receptors are engaged, and additional agonist produces little further signal.
For the laboratory researcher, this has a concrete implication. When designing an experiment with a GHRH receptor agonist, the meaningful portion of the dose-response curve is the low-to-mid range, where hormone output is sensitive to agonist concentration. Saturating amounts erase the ability to detect differences between compounds or between experimental conditions, which is why dose-response piloting is standard practice with this peptide class. It is also why published studies report both the dose used and the growth hormone or IGF-I outcome: the two are tightly coupled through receptor occupancy.
A second theme is pituitary dependence. Because the response to Sermorelin requires an intact GHRH receptor-signaling pathway at the pituitary, the compound can be used in research models to localize where an observed growth hormone deficit originates. If a growth hormone response follows GHRH-receptor stimulation, the pituitary is functioning; if the response is blunted, the defect lies upstream, in the hypothalamus or in receptor signaling itself. This functional probing is one of the most common uses of GHRH(1-29) in modern endocrine research, and it extends naturally to cell-based assays where pituitary cells or GHRH-receptor-expressing lines are used to test receptor agonists and antagonists.
How to evaluate research-grade Sermorelin
For laboratory use, the quality checks are standard for the peptide class:
Sermorelin is a relatively large peptide for its class, so synthetic quality matters. Truncated or deletion impurities are a known risk with long peptides, which is why mass-spectrometry identity confirmation is especially important.
Storage and handling
Standard lyophilized-peptide handling applies:
For a full laboratory protocol, see our peptide reconstitution and laboratory handling guide.
Summary
Sermorelin is the GHRH(1-29) active fragment of growth hormone-releasing hormone and a reference GHRH receptor agonist in endocrine research. Its clinical research history, spanning the pivotal 1987 Lancet study through multicenter pediatric trials and comparative studies against growth hormone, documents its receptor pharmacology and dose-response behavior. As a research tool it is valued for its defined mechanism, pituitary-dependence, and well-characterized literature. As with all research peptides, verify HPLC purity, mass-spectrometry identity, and batch-specific COA, and follow standard lyophilized-peptide handling protocols.
FAQ
What is Sermorelin?
Sermorelin is the N-terminal 29-amino-acid fragment of growth hormone-releasing hormone, GHRH(1-29)-NH2 (GRF 1-29 amide).
How does Sermorelin work?
It activates the GHRH receptor on pituitary somatotrophs to stimulate growth hormone synthesis and release, and requires an intact pituitary.
Is Sermorelin the same as CJC-1295?
No. CJC-1295 is a modified GHRH analog with stabilizing substitutions and, in the DAC form, an albumin-binding complex; Sermorelin is the unmodified GHRH(1-29) fragment.
What purity should research-grade Sermorelin have?
At least 99% by HPLC, identity confirmed by mass spectrometry, and a batch-specific COA.